echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > KraS Inhibitor Latest Data: 96% Disease Control rate in Patients with Non-Small Cell Lung Cancer

    KraS Inhibitor Latest Data: 96% Disease Control rate in Patients with Non-Small Cell Lung Cancer

    • Last Update: 2020-11-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Adagrasib: The differential KRAS G12C selective inhibitor In cells, kraS protein changes between inactivation and activation, and when KRAS binds to bird glycophosphate (GDP), it is inactivated, when it binds to bird glycophosphate (GTP), it is active, and the downstream signaling path can be activated.
    Adagrasib suppresses kras-mediated signal pathlines by "locking" them in inactive images by irreversibly binding them to inactive KRAS G12C mutants.
    KRAS G12C inhibitor regimen (Photo: Mirati.com) Adagrasib has a strong inhibitory effect, with an IC50 in the cell of about 5 nM, and its specificity to KRAS G12C mutants is more than 1000 times that of wild-type KRAS.
    Adgrasib also has good pharmacodynamic properties, a half-life of up to 24 hours, can be distributed in a variety of tissues, and can cross the blood-brain barrier.
    clinical data from patients with non-small cell lung cancer Patients with advanced NSCLC treated with adagrasib monodrides had previously received platinum-containing chemotherapy, and 92% of patients had been treated with PD-1/PD-L1 inhibitors.
    their treatment options are very limited after these two types of treatment are ineffective.
    patient data from Phase 1/1b clinical trials and Phase 2 clinical trials, adagrasib single-drug therapy (dose 600 mg twice daily) achieved a confirmed objective remission rate of 45% (23/51).
    ORR data for the single-drug treatment of patients with advanced NSCLC (Photo: Mirati's official website) it is worth noting that 96% (49/51) of patients benefit from adgrasib single-drug treatment, and 70% (16/23) of patients with confirmed remission have tumors that are more than 40% smaller than the baseline.
    : Mirati's official website, Mirati, also lists a case of an NSCLC patient with a brain metastasis tumor.
    patient was treated with adagrasib, not only was the tumor 67 percent smaller than the baseline, but the metastasis tumor in the brain disappeared.
    Mirati currently plans to register more NSCLC patients with active brain metastasis tumors in Phase 2 clinical trials to further explore the potential of adagrasib in this highly unsatisfying population of patients.
    Phase 2 clinical trial of Adagrasib's single-drug treatment has been completed and the company expects to submit a new drug application (NDA) in the second half of next year for the treatment of patients treated with NSCLC, according to Mirati, a research and development program.
    , Mirati said the development of adgrasib-based combination therapies is key to realizing the full value of KRAS G12C inhibitors.
    Mirati plans to conduct a number of clinical trials to test the efficacy of adagrasib in association with PD-1 inhibitors, EGFR inhibitors, CDK4/6 inhibitors, and in patients with NSCLC and colorectal cancer.
    Mirati has entered into clinical cooperation agreements with Novartis and Boehringer Ingelheim to test the effectiveness of the use of the Adgrasib and Novartis SHP2 inhibitors TNO155, as well as BlingerIngham's Pan KRAS inhibitor BI 1701963.
    at an investor conference, Mirati showed a case that had been treated in adgrasib and TNO155.
    the patient was treated not only with chemotherapy, PD-1/PD-L1 inhibitors, but also with another KRAS G12C inhibitor.
    the patient under combination therapy, the tumor shrunk by 60 percent and he is still being treated.
    case analysis of an NSCLC patient who received a combination therapy of adagrasib and TNO155 (Photo: Mirati's official website) of potential "first-in-class" KRAS G12D inhibitors Positive preclinical results In addition to the KRAS G12C mutation, the KRAS G12D mutation is also a KRAS gene mutation that drives tumors, and it appears much more frequently in patients with colorectal and pancreatic cancer than in KRAS G12C.
    MRTX1133, developed by Mirati, is a potential "first-in-class" KRAS G12D-specific inhibitor that binds irreversibly to activated and inactivated KRAS G12D mutants and inhibits their activity.
    MRTX1133 is more than 1000 times more specific to KRAS G12D than wild-type KRAS and has a half-life of more than 50 hours.
    In in-body trials, MRTX1133 showed dose-dependent inhibition of kras signaling pathline activity and significantly reduced the size of tumors carrying G12D mutations compared to the control group in animal models of pancreatic and colorectal cancers.
    the effects of MRTX1133 in animal models (Photo: Mirati's official website) Mirati also discussed data in the report on the single-drug treatment of colorectal cancer patients and other types of cancer, as well as data on the efficacy of patients with the KRAS G12C and STK11 gene mutations.
    patients who had both mutations had a particularly poor response to chemotherapy and immuno-checkpoint therapy.
    : (1) MIRATI THERAPEUTICS REPORTS INVESTIGATIONAL ADAGRASIB (MRTX849) PRELIMINARY DATA TONING TOLERABILITY AND LONG ANTI-TUMOR ACTIVITY AS WELL AS INITIAL MRTX1133 PRECLINICAL DATA. Retrieved October 25, 2020, from [2] Investor Event at the EORTC-NCI-AACR Virtual Conference. Retrieved October 25, 2020, from [3] Kim et al, (2020) Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients. Cell, (4) Liu et al., (2019). Targeting the untargetable KRAS in cancer therapy. Acta Pharmaceutica Sinica B,
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.